The combination of zolbetuximab plus chemotherapy produced one of the longest overall survival outcomes ever seen for patients with advanced caludin18.2+ gastric or gastroesophageal junction cancer.
Medscape Medical News
The combination of zolbetuximab plus chemotherapy produced one of the longest overall survival outcomes ever seen for patients with advanced caludin18.2+ gastric or gastroesophageal junction cancer.
Medscape Medical News
